An amyloid beta short peptide-mediated brain-targeted delivery system and its preparation method and use

Through the amyloid β short peptide-mediated polypeptide modification complex, specifically adsorbs plasma apolipoprotein, regulating the protein crown component and biological activity of nanodrugs in plasma, the problem of drugs crossing the blood-brain barrier is solved, and the problem of drug crossing the blood-brain barrier is achieved Efficient targeted diagnosis and treatment of brain tumors and other brain diseases.

CN112203693BActive Publication Date: 2024-12-06FUDAN UNIVERSITY
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN201980032453.3
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2018-06-14
Filing Date
2019-05-17
Publication Date
2024-12-06
Estimated Expiration
2039-05-17

AI Technical Summary

Technical Problem

Existing drugs are difficult to cross the blood-brain barrier, resulting in poor targeting efficiency in the application of brain-targeted drug delivery system in vivo, ignoring the impact of body fluid components on drug delivery system.

Method used

Using amyloid β short peptide (SP)-mediated polypeptide modification complex, the specific adsorption of plasma apolipoproteins to regulate the protein coronal components and biological activity of nanodrugs in plasma, to build a target that can cross the blood-brain barrier. To the delivery system, targeting vascular endothelial cells and tumor cells.

Benefits of technology

It has achieved effective trans-blood-brain barrier transport and targeted diagnostic and treatment of drugs, improved the efficiency of drug delivery in brain tumors and other brain diseases, and overcome the shortcomings of traditional targeted nano drugs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN112203693B_ABST
    Figure CN112203693B_ABST
Patent Text Reader

Abstract

A polypeptide-modified complex and targeted delivery system in the pharmaceutical field that can specifically adsorb apolipoproteins in plasma and mediate drug crossing the blood-brain barrier, and its application in the preparation of preparations for diagnosing and treating brain tumors and other brain diseases. The polypeptide fragment (SP) of amyloid β (amyloid, involving a kind) is covalently modified with fluorescent probes, drug molecules and liposome delivery systems. Experiments have shown that the modified delivery system increases its uptake by vascular endothelial cells after reacting with plasma proteins to form a protein corona; the modified liposome delivery system more effectively delivers drugs to the lesion site, significantly improving the therapeutic effect of the drug. After the SP adsorbs plasma proteins, it can mediate drugs to cross the blood-brain barrier and / or target tumor neovascularization and tumor cells. The modified drugs and delivery systems obtain better therapeutic effects in the treatment of brain tumors and other diseases in the brain.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS

[0002] This application claims priority to Chinese invention patent application No. CN201810626652.4 filed on June 19, 2018, which is incorporated herein by reference in its entirety. Technical Field

[0003] The present invention belongs to the field of pharmacy and relates to a brain-targeted delivery system mediated by amyloid β short peptide (SP), and in particular to a polypeptide-modified complex and targeted delivery system that can specifically adsorb apolipoprotein in plasma and mediate drug transport across the blood-brain barrier, and its application in the preparation of preparations for diagnosing and treating brain tumors (including brain metastases and primary brain tumors) and other brain diseases. Background Art

[0004] The prior art discloses that central nervous system diseases have become a serious threat to human health, but the research and development of related new drugs is still very slow. One of the main reasons is that most of the drug molecules in the drugs are difficult to penetrate the blood-brain barrier, and designing drugs or drug delivery systems that can cross the blood-brain barrier is one of the key points and difficulties in the current field of drug research and development. Research has disclosed that brain-targeted drug delivery systems mainly use receptor-mediated methods to cross the blood-brain barrier into the brain, but the current drug design focuses on the binding efficiency of brain-targeted molecules and related receptors on the blood-brain barrier, and often ignores the influence of body fluid components during the in vivo transmission of drug delivery systems, such as: binding to plasma proteins to form a protein corona can greatly affect the targeting and in vivo circulation time of the drug delivery system, etc., thus resulting in poor targeting efficiency of brain-targeted drug delivery systems designed in vitro in in vivo applications. How to design brain-targeted drug delivery systems from a new perspective, accurately regulate their interactions with related proteins or cells during in vivo transmission, including: plasma protein adsorption and dissociation, other cell phagocytosis, protein degradation, immune response, etc., to exert more effective targeting functions, is a hot topic in current industry research.

[0005] Based on the current state of the prior art, the inventors of this application intend to provide a brain-targeted delivery system mediated by amyloid β short peptide (hereinafter referred to as SP), and in particular, to a polypeptide-modified complex and targeted delivery system that can specifically adsorb apolipoproteins in plasma and mediate drug crossing the blood-brain barrier, and its application in the preparation of preparations for diagnosis and treatment of brain tumors (including brain metastases and primary brain tumors) and other brain diseases. The polypeptide-modified targeted delivery system will overcome the defects of traditional targeted nanomedicines by regulating the components and biological activity of the protein corona formed by nanomedicines in plasma, construct an SP-drug complex and SP-modified nano-drug delivery system that can cross the blood-brain barrier and target vascular endothelial cells and tumor cells at the same time, and realize targeted diagnosis and treatment of brain tumors and drug delivery of other brain diseases. Summary of the invention

[0006] The purpose of the present invention is to provide a brain-targeted delivery system mediated by amyloid beta short peptide (SP) in view of the defects of the prior art, and in particular to a polypeptide-modified complex and targeted delivery system that can specifically adsorb apolipoprotein in plasma and mediate drug delivery across the blood-brain barrier, and its application in the preparation of preparations for diagnosis and treatment of peripheral tumors, brain tumors and other brain diseases. The polypeptide-modified targeted delivery system will overcome the defects of traditional targeted nano-drugs by regulating the components and biological activity of the protein corona formed by nano-drugs in plasma, construct an SP-drug complex and SP-modified nano-drug delivery system that can cross the blood-brain barrier and simultaneously target vascular endothelial cells and tumor cells, and realize the targeted diagnosis and treatment of brain tumors (including brain metastases and primary brain tumors) and drug delivery of other brain diseases.

[0007] Before describing the present invention, the terms used in this article are defined as follows:

[0008] The term "SP" refers to: amyloid beta short peptide.

[0009] The term "PLA" means: polylactic acid.

[0010] The term "PLGA" refers to: poly(lactic-co-glycolic acid).

[0011] The term "PCL" means: polycaprolactone.

[0012] The sequence of the SP polypeptide of the present invention (from N to C terminus) is NH 2 -GSNKGAIIGLM-CONH 2 .

[0013] The first aspect of the present invention provides the use of an amyloid β peptide in the preparation of a preparation for mediating drug molecules, fluorescent probes or delivery systems to target brain tumors and / or other brain disease lesions, wherein the amyloid β peptide is an amyloid β peptide that specifically adsorbs apolipoproteins in plasma; preferably, the brain tumor is a brain metastasis and / or a primary brain tumor.

[0014] According to the first aspect of the present invention, the amyloid β short peptide is covalently linked to the imaging substance X to obtain SP-X, which is used for tracing brain tumors and other disease lesions in the brain;

[0015] Preferably, in the SP-X, X is a fluorescent molecule Fluorescein or a near-infrared dye molecule Cy5, Cy5.5, Cy7, IR820, ICG, DiR, DiD, DiI;

[0016] More preferably, the brain tumor is a brain metastasis and / or a primary brain tumor.

[0017] According to the first aspect of the present invention, the amyloid β short peptide is covalently linked to the anti-tumor drug Y to obtain SP-Y, which is used for targeted intervention of brain tumors and other disease lesions in the brain;

[0018] Preferably, in the SP-Y, Y is a small molecule anti-tumor drug such as gefitinib, icotinib, anlotinib, crizotinib, erlotinib, osimertinib, alectinib, paclitaxel, docetaxel, cabazitaxel, doxorubicin, epirubicin, camptothecin, hydroxycamptothecin, 9-nitrocamptothecin or vincristine; and / or

[0019] In the SP-Y, Y is a p53 activation peptide or a polypeptide toxin polypeptide anti-tumor drug;

[0020] More preferably, the brain tumor is a brain metastasis and / or a primary brain tumor.

[0021] According to the use of the first aspect of the present invention, the amyloid β short peptide is connected with polyethylene glycol-Z by a covalent bond to obtain SP-polyethylene glycol-Z, which is used to prepare a nano delivery system;

[0022] Preferably, in the SP-polyethylene glycol-Z, Z is phospholipid, polylactic acid, lactic acid-co-glycolic acid or polycaprolactone; and / or

[0023] Preferably, the nano delivery system is selected from one or more of the following: liposome delivery system, micelle delivery system, nanodisc delivery system and polymer nanoparticle delivery system;

[0024] More preferably, the SP-PEG-phospholipid is used to prepare a liposome delivery system, a micelle delivery system or a nanodisc delivery system; and / or the SP-PEG-PLLA, SP-PEG-Lactic Acid Co-Glycol, SP-PEG-Polycaprolactone is used to prepare a micelle delivery system and a polymer nanoparticle delivery system;

[0025] Further preferably, the liposome delivery system, micelle delivery system, nanodisc delivery system or polymer nanoparticle delivery system is used to encapsulate diagnostic molecules for tracing brain tumors (including brain metastases and primary brain tumors) or other brain disease lesions; preferably, the diagnostic molecule encapsulated by the delivery system is 5-carboxyfluorescein 5-FAM or near-infrared dyes Cy5, Cy5.5, Cy7, IR820, ICG, DiR, DiD, DiI; and / or

[0026] The nanoparticle delivery system, liposome delivery system, micelle delivery system, polymer nanoparticle delivery system or nanodisc delivery system is used to encapsulate antitumor drugs for targeted intervention of brain tumors (including brain metastases and primary brain tumors) or other brain disease lesions; preferably, the drug encapsulated in the drug delivery system is gefitinib, icotinib, anlotinib, crizotinib, erlotinib, osimertinib, alectinib, paclitaxel, docetaxel, cabazitaxel, doxorubicin, epirubicin, camptothecin, hydroxycamptothecin, 9-nitrocamptothecin, vincristine, p53 activation peptide or polypeptide toxin;

[0027] More preferably, the brain tumor is a brain metastasis and / or a primary brain tumor.

[0028] The second aspect of the present invention provides an amyloid β short peptide for preparing a preparation for mediating drug molecules, fluorescent probes or delivery systems targeting brain tumors or other brain disease lesions, wherein the amyloid β short peptide is an amyloid β short peptide that specifically adsorbs apolipoproteins in plasma; preferably, the brain tumor is a brain metastasis and / or a primary brain tumor.

[0029] The third aspect of the present invention provides a tracer molecule for brain tumors and other disease lesions in the brain, wherein the tracer molecule is the amyloid β short peptide described in the second aspect connected with an imaging substance X by a covalent bond to obtain SP-X;

[0030] Preferably, in the SP-X, X is a fluorescent molecule Fluorescein or a near-infrared dye molecule Cy5, Cy5.5, Cy7, IR820, ICG, DiR, DiD, DiI;

[0031] More preferably, the brain tumor is a brain metastasis and / or a primary brain tumor.

[0032] The fourth aspect of the present invention provides a drug for targeted intervention of brain tumors and other disease lesions in the brain, wherein the drug is the amyloid β short peptide described in the second aspect connected with the anti-tumor drug Y by a covalent bond to prepare SP-Y;

[0033] Preferably, in the SP-Y, Y is a small molecule anti-tumor drug such as gefitinib, icotinib, anlotinib, crizotinib, erlotinib, osimertinib, alectinib, paclitaxel, docetaxel, cabazitaxel, doxorubicin, epirubicin, camptothecin, hydroxycamptothecin, 9-nitrocamptothecin or vincristine; and / or

[0034] In the SP-Y, Y is a p53 activation peptide or a polypeptide toxin polypeptide anti-tumor drug;

[0035] More preferably, the brain tumor is a brain metastasis and / or a primary brain tumor.

[0036] The fifth aspect of the present invention provides a nano delivery system, the nano delivery system comprising SP-polyethylene glycol-Z prepared by connecting the amyloid β short peptide described in the second aspect with polyethylene glycol-Z by covalent bonds;

[0037] Preferably, in the SP-polyethylene glycol-Z, Z is phospholipid, polylactic acid, lactic acid-co-glycolic acid or polycaprolactone;

[0038] More preferably, the nano delivery system is selected from one or more of the following: liposome delivery system, micelle delivery system, nanodisc delivery system and polymer nanoparticle delivery system;

[0039] Further preferably, when the SP-PEG-Z is SP-PEG-phospholipid, the nano-delivery system is selected from one or more of the following: liposome delivery system, micelle delivery system and nanodisc delivery system; when the SP-PEG-Z is SP-PEG-polylactic acid, SP-PEG-lactic acid-co-glycolic acid, SP-PEG-polycaprolactone, the nano-delivery system is a micelle delivery system and / or a polymer nanoparticle delivery system;

[0040] Further preferably, the liposome delivery system, micelle delivery system, nanodisc delivery system or polymer nanoparticle delivery system is used to encapsulate diagnostic molecules for tracing brain tumors or other brain disease lesions; preferably, the diagnostic molecules encapsulated by the delivery system are 5-carboxyfluorescein 5-FAM or near-infrared dyes Cy5, Cy5.5, Cy7, IR820, ICG, DiR, DiD, DiI; and / or

[0041] Further preferably, the nanoparticle delivery system, liposome delivery system, micelle delivery system, polymer nanoparticle delivery system or nanodisc delivery system is used to encapsulate antitumor drugs for targeted intervention of brain tumors (including brain metastases and primary brain tumors) or other brain disease lesions; preferably, the drug encapsulated in the drug delivery system is gefitinib, icotinib, anlotinib, crizotinib, erlotinib, osimertinib, alectinib, paclitaxel, docetaxel, cabazitaxel, doxorubicin, epirubicin, camptothecin, hydroxycamptothecin, 9-nitrocamptothecin, vincristine, p53 activation peptide or polypeptide toxin;

[0042] More preferably, the brain tumor is a brain metastasis and / or a primary brain tumor.

[0043] The sixth aspect of the present invention provides a method for preparing the nano delivery system according to the fifth aspect, the method comprising the following steps:

[0044] Weighing natural phospholipids, cholesterol, methoxy-PEG-DSPE, SP-polyethylene glycol-Z, model drugs or probe molecules, dissolving them in a solvent, forming a film, hydrating, passing through the film, and removing free probe molecules or drugs by column chromatography to prepare the nano delivery system; and / or

[0045] The nano delivery system is prepared by weighing natural phospholipids, cholesterol, methoxy-PEG-DSPE, and SP-polyethylene glycol-Z, dissolving them in a solvent, forming a film, hydrating, passing the film, actively encapsulating probe molecules or drugs, and removing free probe molecules or drugs by column chromatography.

[0046] The seventh aspect of the present invention provides a pharmaceutical composition, which comprises: 1) the amyloid β short peptide described in the second aspect, the tracer molecule described in the third aspect, the drug described in the fourth aspect and / or the nanodelivery system described in the fifth aspect; and 2) a pharmaceutically acceptable carrier.

[0047] The eighth aspect of the present invention provides a diagnostic preparation, which comprises: the amyloid β short peptide described in the second aspect, the tracer molecule described in the third aspect, the drug described in the fourth aspect and / or the nanodelivery system described in the fifth aspect.

[0048] The ninth aspect of the present invention provides a method for treating brain diseases, the method comprising: administering the amyloid β short peptide of the second aspect, the tracer molecule of the third aspect, the drug of the fourth aspect and / or the nano delivery system of the fifth aspect to a subject in need;

[0049] Preferably, the brain disease is a brain tumor or other brain disease;

[0050] More preferably, the brain tumor is a brain metastasis and / or a primary brain tumor.

[0051] The tenth aspect of the present invention provides a method for diagnosing brain tumors and other disease lesions in the brain, the method comprising: administering the amyloid β short peptide described in the second aspect, the tracer molecule described in the third aspect, the drug described in the fourth aspect and / or the nanodelivery system described in the fifth aspect to a subject in need; preferably, the brain tumor is a brain metastasis and / or a primary brain tumor.

[0052] The eleventh aspect of the present invention provides a targeted intervention method for brain tumors or other brain disease lesions, the method comprising: administering the amyloid β short peptide described in the second aspect, the tracer molecule described in the third aspect, the drug described in the fourth aspect and / or the nanodelivery system described in the fifth aspect to a subject in need; preferably, the brain tumor is a brain metastasis and / or a primary brain tumor.

[0053] The twelfth aspect of the present invention provides a drug-mediated method, comprising: administering the amyloid β short peptide described in the second aspect, the tracer molecule described in the third aspect, the drug described in the fourth aspect and / or the nanodelivery system described in the fifth aspect to a subject in need; preferably, the brain tumor is a brain metastasis and / or a primary brain tumor.

[0054] In the present invention, the clearance mechanism of amyloid β in the brain is simulated, which uses apolipoprotein (such as Apoliportein E, Apoliprotein A1 and Apoliprotein J) as a molecular chaperone and is transported to the periphery through receptor mediation. A short peptide (SP) that can specifically bind to the lipid binding domain of apolipoprotein is designed with amyloid β as a template. The short peptide is modified on the surface of liposomes to specifically adsorb apolipoprotein in plasma during blood circulation in the body and maintain its biological activity, thereby utilizing the apolipoprotein to bind to multiple receptors on the blood-brain barrier [including Low-density lipoprotein-related protein 1 (LRP-1), Scavenger receptor class B member 1 (SRB1) and Low-density lipoprotein-related protein 2(LRP-2)] binds to mediate the transport of liposomes into the brain; the polypeptide-modified liposomes can overcome the defects of traditional targeted nanomedicines by regulating the composition and biological activity of the protein corona formed by nanomedicines in plasma, construct SP-drug complexes and SP-modified nanodrug delivery systems that can cross the blood-brain barrier and target vascular endothelial cells and tumor cells at the same time, thereby achieving targeted diagnosis and treatment of brain tumors and drug delivery of other brain diseases.

[0055] In the present invention, SP is covalently modified on materials such as polyethylene glycol-distearoylphosphatidylethanolamine (PEG-DSPE), polyethylene glycol-polylactic acid (PEG-PLA), polyethylene glycol-lactic acid-co-glycolic acid (PEG-PLGA), polyethylene glycol-polycaprolactone (PEG-PCL), etc. to construct SP short peptide-modified liposomes, micelles, nanodiscs, nanoparticles and other delivery systems.

[0056] The SP-modified nanodelivery system can encapsulate anti-tumor drugs such as gefitinib, icotinib, anlotinib, crizotinib, erlotinib, osimertinib, alectinib, paclitaxel, docetaxel, cabazitaxel, doxorubicin, epirubicin, camptothecin, hydroxycamptothecin, 9-nitrocamptothecin, vincristine, p53 activating peptide, bee venom peptide, scorpion venom peptide, etc.; and can encapsulate fluorescent substances such as FAM, near-infrared dyes Cy5, Cy5.5, Cy7, IR820, ICG, DiR, DiD, DiI, etc.

[0057] In the present invention, the SP-modified drugs or probes include drugs such as doxorubicin, epirubicin, p53 activation peptide, polypeptide toxins, etc. formed by reacting maleimide hexahydrazine derivatives to form pH-sensitive hydrazone bonds, or drugs such as gefitinib, icotinib, anlotinib, crizotinib, erlotinib, osimertinib, alectinib, paclitaxel, docetaxel, cabazitaxel, camptothecin, hydroxycamptothecin, 9-nitrocamptothecin, vincristine, p53 activation peptide, polypeptide toxins, etc. formed by reacting 3-(2-pyridyldithiol) propionic acid derivatives to form disulfide bonds, or drugs such as gefitinib, icotinib, anlotinib, crizotinib, erlotinib, osimertinib, alectinib, paclitaxel, docetaxel, cabazitaxel, camptothecin, hydroxycamptothecin, 9-nitrocamptothecin, vincristine, p53 activation peptide, polypeptide toxins, etc., or fluorescent probes connected by stable chemical bonds, such as Fluorescein, Cy5, Cy5.5, Cy7, ICG, and IR820.

[0058] Furthermore, the present invention provides the use of an amyloid β peptide in the preparation of a preparation for mediating drug molecules, fluorescent probes or delivery systems targeting brain tumors (including brain metastases and primary brain tumors) or other brain disease lesions, wherein the amyloid β peptide (SP) is an amyloid β peptide that specifically adsorbs apolipoproteins in plasma.

[0059] The amyloid β short peptide (SP) is covalently linked to an imaging substance X to obtain SP-X, which is used for tracing brain tumors (including brain metastases and primary brain tumors) and other disease lesions in the brain; in the SP-X, X is a fluorescent molecule Fluorescein or a near-infrared dye molecule Cy5, Cy5.5, Cy7, IR820, ICG, DiR, DiD, DiI;

[0060] The amyloid β short peptide (SP) is covalently linked to the anti-tumor drug Y to obtain SP-Y, which is used for targeted intervention of brain tumors (including brain metastases and primary brain tumors) and other disease lesions in the brain; in the SP-Y, Y is gefitinib, icotinib, anlotinib, crizotinib, erlotinib, osimertinib, alectinib, paclitaxel, docetaxel, cabazitaxel, doxorubicin, epirubicin, camptothecin, hydroxycamptothecin, 9-nitrocamptothecin or vincristine small molecule anti-tumor drug; in the SP-Y, Y is p53 activation peptide or polypeptide toxin polypeptide anti-tumor drug;

[0061] The amyloid β short peptide (SP) is connected to polyethylene glycol-Z by a covalent bond to obtain SP-polyethylene glycol-Z, which is used to prepare a nano delivery system; in the SP-polyethylene glycol-Z, Z is phospholipid, polylactic acid (PLA), poly(lactic acid-glycolic acid) copolymer (PLGA) or polycaprolactone (PCL);

[0062] The SP-polyethylene glycol-phospholipid described in the present invention is used to prepare a liposome delivery system, a micelle delivery system or a nanodisc delivery system;

[0063] The SP-polyethylene glycol-polylactic acid, SP-polyethylene glycol-lactic acid copolymer, and SP-polyethylene glycol-polycaprolactone described in the present invention are used to prepare micelle delivery systems and polymer nanoparticle delivery systems;

[0064] The liposome delivery system, micelle delivery system, nanodisc delivery system or polymer nanoparticle delivery system described in the present invention is used to encapsulate diagnostic molecules for tracing brain tumors (including brain metastases and primary brain tumors) or other brain disease lesions; the diagnostic molecules encapsulated by the delivery system are 5-carboxyfluorescein 5-FAM or near-infrared dyes Cy5, Cy5.5, Cy7, IR820, ICG, DiR, DiD, DiI;

[0065] The nanoparticle delivery system, liposome delivery system, micelle delivery system, polymer nanoparticle delivery system or nanodisc delivery system described in the present invention is used to encapsulate anti-tumor drugs for targeted intervention of brain tumors (including brain metastases and primary brain tumors) or other brain disease lesions; the encapsulated drugs are gefitinib, icotinib, anlotinib, crizotinib, erlotinib, osimertinib, alectinib, paclitaxel, docetaxel, cabazitaxel, doxorubicin, epirubicin, camptothecin, hydroxycamptothecin, 9-nitrocamptothecin, vincristine, p53 activation peptide or polypeptide toxin.

[0066] More specifically, the present invention is implemented by the following technical solutions:

[0067] 1. Preparation of SP-modified liposome delivery system

[0068] SP containing cysteine ​​thiol group was reacted with maleimide-PEG-DSPE in phosphate buffer at pH 7.4, and the product was lyophilized after purification to prepare SP-PEG-DSPE for use.

[0069] Weigh a certain amount of natural phospholipids, cholesterol, methoxy-PEG-DSPE (mPEG-DSPE), SP-PEG-DSPE, model drugs or probe molecules, dissolve them in a solvent, form a film, hydrate, pass the membrane through a liposome extruder, remove free probe molecules or drugs by column chromatography, and prepare SP polypeptide-modified liposomes, and characterize their particle size and surface potential by a dynamic light scattering particle size meter. Or weigh a certain amount of natural phospholipids, cholesterol, methoxy-PEG-DSPE (mPEG-DSPE), SP-PEG-DSPE, dissolve them in a solvent, form a film, hydrate, pass the membrane through a liposome extruder, actively encapsulate probe molecules or drugs, remove free probe molecules or drugs by column chromatography, and prepare SP-modified liposomes, and characterize their particle size and surface potential by a dynamic light scattering particle size meter.

[0070] 2. Experiment on the effect of SP-modified delivery system on its binding activity after co-incubation with plasma to form a protein corona.

[0071] After the SP-modified delivery system was incubated with fresh plasma for a period of time, its binding activity with the LRP-1 receptor was detected by western blot and radioactive labeling methods. The SP-modified delivery system not incubated with serum and the delivery system without SP modification were used as negative controls.

[0072] 3. Experiment on the effect of SP modification on the uptake of the delivery system by endothelial cells.

[0073] The uptake of SP-modified and unmodified delivery systems by endothelial cells (such as bEND.3 cells) was compared before and after serum incubation.

[0074] 4. Evaluation of the ability of the SP-modified delivery system to cross the BBB in normal mice.

[0075] Normal mice (such as Kunming strain, C57BL / 6, etc.) were injected with the delivery system loaded with luciferin through the tail vein, and the accumulation of SP-modified and unmodified delivery systems in the mouse brain at different time points was compared.

[0076] 5. Evaluation of the pharmacokinetics of the SP-modified delivery system in normal rats

[0077] Normal SD rats were injected with fluorescein DiI-labeled peptide-modified and unmodified delivery systems through the tail vein. Blood was collected at different time points, and plasma was separated. The DiI content in plasma was detected by fluorescence quantitative analysis to evaluate the pharmacokinetics of the SP-modified delivery system in rats.

[0078] 6. Evaluation of the immunogenicity of the SP-modified delivery system in normal mice

[0079] Peptide-modified and unmodified delivery systems containing Lipid A were prepared and injected intraperitoneally into Balb / c mice once every seven days for four weeks. Blood was collected from the eye sockets on the seventh day after each injection, and plasma was collected and frozen for future use. The ELISA method was used to detect the levels of IgG and IgM against PEG and SP produced in mice at different time points to evaluate immunogenicity.

[0080] 7. Evaluation of the anti-tumor effect of SP-modified delivery system in vivo

[0081] The SP-modified delivery system, unmodified peptide delivery system, free drug and normal saline were injected into the tail vein of nude mice bearing an orthotopic U87 glioma model. The median survival time of the model nude mice, tumor tissue cell apoptosis and neovascularization density were used as indicators to evaluate the in vivo anti-tumor effect of the SP-modified delivery system.

[0082] Experiments of the present invention show that the SP-mediated drug or drug delivery system targets cells and tissues with high expression of LRP-1, has the ability to cross biological membrane barriers, especially the blood-brain barrier (BBB), and can be used for targeted diagnosis and treatment of brain tumors (including brain metastases and primary brain tumors) and other diseases.

[0083] Experiments of the present invention show that SP is modified on the surface of the drug delivery system, binds to apolipoproteins in plasma, forms a protein corona, and increases the uptake of vascular endothelial cells; SP can simultaneously mediate the drug across the blood-brain barrier, and / or target tumor neovascularization and tumor cells, and the modified drugs and drug delivery systems can achieve better therapeutic effects in the treatment of brain tumors (including brain metastases and primary brain tumors) and other diseases in the brain.

[0084] BRIEF DESCRIPTION OF THE DRAWINGS

[0085] Figure 1 .In vitro binding characterization of SP-modified liposomes with plasma proteins

[0086] SP was modified on the surface of liposomes by chemical coupling to obtain SP-sLip, which was mixed with mouse plasma and incubated at 37°C for 1 hour. The liposome precipitate containing the protein corona was obtained by high-speed centrifugation. The plasma protein components adsorbed by liposomes were analyzed by Biorad 4%-20% gradient SDS-PAGE and rapid silver staining (such as attached Figure 1 The results showed that compared with the long-circulating liposomes (sLip) modified with methoxypolyethylene glycol, the plasma protein adsorbed by SP-sLip was significantly increased at 45KDa (band 1), 38KDa (band 2) and 25KDa (band 3). The PAGE gels corresponding to the three identical positions of the two were subjected to LC-MS / MS and western blot (see Appendix Figure 1 The results of the analysis showed that the three proteins identified were ApoJ, ApoE and ApoA1 from mice. The semi-quantitative Western blot method also confirmed that the adsorption of the three apolipoproteins by SP-sLip was significantly increased compared with that of sLip (see attached Figure 1 CE).

[0087] Figure 2 .Identification of fluorescently labeled sLip and SP-sLip adsorbing plasma functional apolipoproteins in vivo

[0088] In order to verify that the target peptide-modified liposomes can still adsorb the relevant target protein after systemic administration in animals, we injected an equal amount of DiI fluorescently labeled liposomes into mice via the tail vein, collected blood 1 hour later, and separated the liposomes containing the protein corona in the plasma. Figure 2As shown in A, the western blot method detected that the content of three apolipoproteins (ApoJ, ApoE, ApoA1) adsorbed by liposomes with the same content in mice was significantly different. This result proves that compared with ordinary liposomes, SP-modified liposomes (SP-sLip) can quickly and specifically adsorb apolipoproteins in plasma proteins in mice. (See Appendix Figure 2 BD semi-quantitative analysis)

[0089] Figure 3 Evaluation of the binding activity of sLip and SP-sLip to LRP-1 receptor after adsorption of plasma protein

[0090] SP-modified liposomes (SP-sLip) can specifically adsorb the recombinant protein LRP-1 in the solution (such as Figure 3 We confirmed by western blot that SP-sLip still retained the ability to bind to LRP-1 after pre-incubation with ApoE (see attached Figure 3 BC). Figure 3 DE proved through ELISA experiments that both free SP and modified liposomes (SP-sLip) can compete for the interaction between SP and antibodies fixed on 96-well plates, while SP-sLip after plasma incubation loses the ability to compete for antibody binding, indicating that after the SP on the surface of liposomes binds to plasma proteins such as ApoE, its functional domain is blocked. Apolipoproteins such as ApoE that specifically bind to the surface of SP-sLip have the activity of binding to the BBB receptor LRP-1, becoming an effective way for SP-sLip to cross the BBB and enter the brain.

[0091] Figure 4 . Uptake of liposomes by endothelial cells before and after plasma incubation

[0092] After SP-modified liposomes (SP-sLip) were co-incubated with plasma to form a protein corona, endothelial cells increased their uptake (e.g., Figure 4 AB).

[0093] Figure 5 Evaluation of pharmacokinetic parameters and immunogenicity of SP-modified liposomes in mice

[0094] SP was modified on the surface of liposomes (SP-sLip) and did not affect the pharmacokinetic parameters of liposomes in vivo (such as Figure 5 A), nor did it increase the immunogenicity of ordinary long-circulating liposomes (using IgG and IgM in the blood as evaluation indicators, as shown in the attached Figure 5 BD). Figure 6 Evaluation of brain penetration efficiency of SP-modified liposomes in mice

[0095] By detecting fluorescein in the mouse brain in vivo, it was found that the amount of fluorescein crossing the BBB in the SP-sLip group was significantly higher than that in the sLip group, indicating that SP can mediate the delivery system across the blood-brain barrier.

[0096] Figure 7 .In vivo efficacy of doxorubicin-loaded liposomes against glioma

[0097] The median survival time of mice in the normal saline group, DOX group, sLip / DOX group, and SP-sLip / DOX group were 27 days, 31 days, 33 days, and 50 days, respectively. SP-modified liposomes can significantly prolong the median survival time of mice with brain orthotopic tumor model.

[0098] Figure 8 .Effects of doxorubicin-loaded liposomes on angiogenesis in tumor tissues

[0099] The vascular density in the tumor tissue of the SP-modified liposome-encapsulated doxorubicin group (SP-sLip / DOX) was significantly lower than that of the unmodified group (sLip / DOX), indicating that SP can mediate the delivery system to target tumor neovascularization.

[0100] Fig. 9 Effects of doxorubicin-loaded liposomes on apoptosis of glioma cells

[0101] The number of apoptotic cells in the tumor tissue of the SP-modified liposome-encapsulated doxorubicin group (SP-sLip / DOX) was significantly higher than that of the unmodified group, indicating that SP can mediate the drug delivery system to target tumor cells.

[0102] Fig.10 .Safety evaluation

[0103] SP did not show cytotoxicity on the neuronal cell line PC12 cultured in vitro (e.g. Fig.10 A), while the tissue sections of the organs of mice in the SP-modified liposome-encapsulated doxorubicin group (SP-sLip / DOX) showed no obvious abnormalities (see Appendix Fig.10 B), indicating that SP modification on the liposome surface did not cause toxic side effects.

[0104] Best Mode for Carrying Out the Invention

[0105] The present invention is further described below by means of specific examples. However, it should be understood that these examples are only used for more detailed and specific description and should not be understood as limiting the present invention in any form.

[0106] This section generally describes the materials and test methods used in the experiments of the present invention. Although many materials and operating methods used to achieve the purpose of the present invention are well known in the art, the present invention is still described as detailed as possible. It is clear to those skilled in the art that in the context, if not specifically stated, the materials and operating methods used in the present invention are well known in the art.

[0107] Example 1 Preparation of liposomes

[0108] Preparation of liposomes sLip / DiI and SP-sLip / DiI:

[0109] Preparation of liposome sLip / DiI: weigh 7.85 mg of natural phospholipids (HSPC) for preparing liposome membranes; 3.35 mg of cholesterol; 2.78 mg of mPEG-2000-DSPE; and 0.4 mg of DiI, dissolve in 10 mL of CHCl3, evaporate in a 40-degree water bath to form a membrane, vacuum dry to remove the organic solvent, dissolve the membrane in 1 mL of double-distilled water, shake well in a 60-degree water bath to hydrate, and extrude in a liposome extruder with pore sizes of 400 nm, 200 nm, and 100 nm to obtain sLip / DiI;

[0110] Preparation of liposome SP-sLip / DiI: Weigh 50mg Mal-PEG-DSPE and dissolve it in 5mL CHCl3 to form a film at 37 degrees. After vacuum drying for half an hour, dissolve it in 4mL double distilled water, hydrate at 37 degrees, and remove large particles by ultrasound. Weigh 26mg SP-Cys protein and dissolve it in 2mL double distilled water, mix it with the above membrane material solution, rinse the container with 1mL double distilled water, mix it, add 40μLEDTA solution (500mM, pH 8.0), 3mL PB solution (0.1M, pH 7.4), stir at room temperature for 6h to make it free of flocculent precipitation. Use 8000-10000Da pore size dialysis membrane, dialyze in distilled water for 48h-72h, and the resulting solution freeze-dried product is SP-PEG-DSPE;

[0111] Weigh 7.85 mg HSPC, 3.35 mg cholesterol, 1.67 mg mPEG-2000-DSPE, 1.82 mg SP-PEG-DSPE, and 0.4 mg DiI as the membrane material for preparing liposomes, and dissolve them in 10 mL CHCl 3 The film was suspended and evaporated in a 40-degree water bath, and the organic solvent was removed by vacuum drying. The film was dissolved in 1 mL of double-distilled water and shaken in a 60-degree water bath for hydration. SP-sLip / DiI was obtained by extruding through 400 nm, 200 nm, and 100 nm pores in a liposome extruder.

[0112] Preparation of liposomes sLip / DOX and SP-sLip / DOX:

[0113] Preparation of liposome sLip / DOX: Weigh 7.85 mg HSPC, 3.35 mg cholesterol and 2.78 mg mPEG-2000-DSPE for preparing liposome membrane, dissolve in 10 mL CHCl3, evaporation in a water bath at 40 degrees to form a membrane, vacuum dry to remove organic solvent, dissolve the membrane in 1 mL ammonium sulfate solution (0.32 M), shake well in a water bath at 60 degrees to hydrate, extrude in a liposome extruder through 400 nm, 200 nm, and 100 nm pores to obtain sLip hydrated with ammonium sulfate solution, replace with physiological saline solvent through a G50 elution column, add doxorubicin aqueous solution and mix (drug-lipid ratio 1:10), remove unencapsulated doxorubicin through a G50 chromatography column to obtain sLip / DOX;

[0114] Preparation of liposome SP-sLip / DOX: Weigh the membrane materials for preparing liposomes: HSPC: 7.85 mg, cholesterol: 3.35 mg, mPEG-2000-DSPE: 1.67 mg, SP-PEG-DSPE: 1.82 mg, and the remaining steps are the same as above (preparation of liposome sLip / DOX) to obtain SP-sLip / DOX.

[0115] Example 2 The binding activity of liposomes to LRP-1 receptor after forming a protein corona in serum and its influence on uptake by vascular endothelial cells

[0116] Characteristics of liposomes forming a protein corona in serum:

[0117] Serum (containing protease inhibitors and EDTA as anticoagulant) from C57BL / 6 mice was mixed with liposomes in a ratio of 1:1, incubated at 37°C for 1 hour, centrifuged at 15,000 rpm for 30 minutes, washed twice with cold PBS, and dissolved in 30 μL PBS. Serum was used as a positive control and PBS was used as a negative control. 6 μL of SDS-PAGE loading buffer and 3 μL of β-mercaptoethanol were added, and the protein was denatured by boiling for 10 minutes. Proteins of different molecular weights were separated by 4-20% polyacrylamide gel, and the color was developed by a fast silver staining kit. The obvious difference bands in the PAGE gel (as indicated by the red arrow) and the same position of the control were cut off, digested with trypsin, resuspended in 0.1% formic acid solution, and the protein components of each band were analyzed by LC-MS / MS. The experimental results are shown in the figure. Figure 1 As shown;

[0118] The in vivo experiment was carried out as follows: the fluorescent DiI-labeled peptide-modified and unmodified liposomes were injected into C57BL / 6 mice via the tail vein, and blood was collected 1 h later and plasma was separated by low-speed centrifugation. The protein corona separation method was the same as the in vitro experiment above, and the protein corona components adsorbed in vivo were identified by SDS-PAGE and western blot methods, such as Figure 2 shown.

[0119] Binding activity of SP-sLip to LRP-1 receptor before and after serum incubation:

[0120] The ELISA method was used to detect the binding activity of SP-sLip and SP antibody before and after serum incubation, so as to determine the changes in the active binding domain of SP and the receptor after the interaction with plasma proteins and detect the activity of the adsorbed apolipoprotein. The specific operation was as follows: 0.1 μg SP-PEG-DSPE was added to each well of the ELISA plate, incubated at room temperature overnight, washed 3 times with PBS, blocked with 3% BSA for 1 hour, the BSA solution was removed, SP antibody was added and incubated at 37°C for 1 hour, washed three times with PBS, liposomes pre-incubated with serum or PBS and graded diluted were added, incubated at 37°C for 1 hour, washed three times with PBS, and the corresponding horseradish peroxidase-labeled secondary antibody was added. After 1 hour, it was reacted with TMB colorimetric solution for 3-15 minutes, and stained with 2M H 2 SO 4 Stop the reaction and measure the absorbance at 450nm. The experimental results are as follows: Figure 3 shown.

[0121] Effect of SP-sLip on uptake by vascular endothelial cells after forming a protein corona in serum:

[0122] Recovery of endothelial cells bEND3: Frozen bEND3 cells were quickly thawed and transferred to a centrifuge tube pre-filled with culture medium. After centrifugation at 1000r / min for 3min, the supernatant was discarded, and DMEM culture medium containing 10% FBS was added. The cells were gently blown and evenly added to the culture dish and mixed. The cell morphology and growth were observed under a microscope and placed at 37°C and 5% CO 2 , cultured in an incubator with a relative humidity of 95%;

[0123] Culture of vascular endothelial cells bEND3: Observe the growth of bEND3 cells, i.e., cell number, morphology, and adhesion. Aspirate and discard the old culture medium, add fresh DMEM culture medium containing 10% FBS, mix well, and incubate at 37°C and 5% CO. 2 , continue to culture in a saturated humidity incubator, observe cell growth every day, subculture every 2-3 days, and the cells are in the logarithmic growth phase for about 10 days and can be used for in vitro cell experiments;

[0124] Passaging of endothelial cells bEND3: discard the culture medium, rinse twice with PBS, add a small amount of 0.25% trypsin, place in an incubator for 1 min, then add 2-3 mL of culture medium to terminate digestion, divide the cell suspension into several centrifuge tubes, discard the supernatant after centrifugation, add new culture medium, transfer to a culture dish, and place in an incubator for culture;

[0125] Cryopreservation of endothelial cells bEND3: After the cell experiment is completed, cryopreserve the cells for next use. Prepare the cryopreservation solution (containing 10% DMSO and 90% fetal bovine serum) in advance and precool it at 4°C. After digesting the cells with trypsin, add the precooled cryopreservation solution and mix it gently with a dropper. Add 1mL of cell solution to each cryopreservation tube, seal it, mark the name of the cryopreserved cells and the cryopreservation date, place it at -80°C overnight, store it in a liquid nitrogen tank and register it for record;

[0126] bEND3 of appropriate density was inoculated in a 6-well plate and cultured in a cell culture incubator overnight. Fluorescein DiI-labeled liposomes (incubated with serum and not incubated with serum) were diluted 50 times with serum-free DMEM medium, 1 ml was added to each well, and incubated with cells for 4 hours. The culture medium was aspirated, and the cells were quickly washed twice with PBS. The cells were digested with trypsin, and the digestion was terminated with serum-containing medium. The cells were centrifuged and washed once with PBS. Finally, the cells were dispersed in 300 μL of PBS, and the percentage of positive cells that took up DiI-encapsulated liposomes and the fluorescence intensity (excitation wavelength 555 nm, emission wavelength 570 nm) were measured by flow cytometry. The experimental results are shown in Figure 2. Figure 4 As shown;

[0127] Effects of SP modification on in vivo pharmacokinetic parameters and immunogenicity of liposomes:

[0128] SD rats, 3 in each group, were injected with sLip / DiI and SP-sLip / DiI through the tail vein. Blood was collected from the tail (EDTA anticoagulation) before administration, 5min, 30min, 1h, 2h, 4h, 8h, 12h and 24h respectively. The supernatant was separated from the blood samples, and the DiI in the plasma was diluted with normal rat serum. The fluorescence spectrophotometer was used for quantification (excitation wavelength 555nm, emission wavelength 570nm). The experimental results are shown in Figure 5 As shown in a, sLip and SP-sLip loaded with Lipid A were intraperitoneally injected into Balb / c mice once every 7 days. Blood was collected on the seventh day after each injection for later use. The ELISA method was used to detect the levels of IgG and IgM against PEG and SP in the mice at different time points. The experimental results are shown in Figure 5 As shown in bc.

[0129] Example 3 SP-modified liposomes can cross the BBB

[0130] In vivo experiments confirmed that SP-modified liposomes labeled with fluorescein DiI (SP-sLip / DiI) can cross the blood-brain barrier:

[0131] Fluorescently labeled SP-sLip / DiI (phospholipid content 10 mg / mL, DiI content 0.4 mg / mL) was injected into the tail vein of C57BL / 6 mice (10 μL / g). After 1 hour, the mice were anesthetized with ether, and the brain tissue was removed and fixed in 4% paraformaldehyde for 24 hours, dehydrated with 30% sucrose, embedded in OCT, frozen, and sectioned. The nucleus was stained with DAPI, and the blood vessels were labeled with CD31 antibody. The cells were observed under a microscope and photographed. Fluorescein DiI-labeled methoxy liposomes were used as controls and processed in the same way. The experimental results are shown in Figure 2. Figure 6 shown.

[0132] Example 4 In vivo pharmacodynamics experiment of SP-sLip loaded with doxorubicin

[0133] Median survival of mice with orthotopic tumor model:

[0134] Establishment of nude mouse model of brain glioma: U87 cells in the logarithmic growth phase were obtained, digested and counted, suspended in an appropriate amount of PBS buffer, and inoculated with 6×10 cells per nude mouse. 5 cells (dispersed in 5 μL PBS buffer). Before the experiment, nude mice were anesthetized with 7% chloral hydrate and fixed with a brain stereotaxic instrument. The suspended cells were inoculated in the striatum (i.e., 0.6 mm forward, 1.8 mm to the right, and 3 mm deep) from the anterior bregma. The status of the nude mice after surgery was regularly observed.

[0135] The nude mice with orthotopic brain tumor model were randomly divided into 4 groups (n=13). The body weight of the mice was recorded on the 7th, 9th, 11th, 13th and 15th days respectively. 200 μL of normal saline, doxorubicin, sLip / DOX and SP-sLip / DOX were injected into the tail vein. The single injection dose of doxorubicin was 2 mg / kg. The survival time of the nude mice was recorded. The experimental results are shown in Table 1. Figure 7 shown.

[0136] Experiment on inhibition of angiogenesis and promotion of tumor cell apoptosis by SP-sLip loaded with doxorubicin:

[0137] On the 18th day after the administration of the orthotopic glioma model mice, chloral hydrate anesthesia was performed, brain tissue was isolated, fixed with paraformaldehyde, dehydrated, and embedded in paraffin for sectioning. The inhibitory effect on neovascularization was observed by immunofluorescence staining of CD31 antibody, and the degree of apoptosis of tumor cells was detected by terminal deoxynucleotidyl transferase (TDT)-mediated dUTP nick end labeling (TUNEL). The confocal fluorescence microscope was used to observe and take pictures. The experimental results are shown in Figure 2. Figure 8 , as shown in 9.

[0138] Safety evaluation: SP with gradient concentrations was co-cultured with the neural cell line PC12 to evaluate its cytotoxicity under in vitro culture conditions. At the same time, the heart, liver, spleen, lung, and kidney tissues of mice in each treatment group of the orthotopic tumor pharmacodynamics test were dissected and fixed in 4% paraformaldehyde PBS solution, embedded in paraffin, and sliced. HE staining was performed, and the tissues were observed and photographed under a microscope. The experimental results are shown in the figure. Fig.10 shown.

[0139] Although the present invention has been described to a certain extent, it is obvious that appropriate changes in various conditions can be made without departing from the spirit and scope of the present invention. It is understood that the present invention is not limited to the embodiments described, but belongs to the scope of the claims, which includes equivalent replacements of each factor described.

Claims

1. Use of an amyloid β short peptide in the preparation of a preparation for mediating a nano-delivery system to cross the blood-brain barrier by binding to a receptor on the blood-brain barrier to target brain tumors, wherein the amyloid β short peptide is an amyloid β short peptide that specifically adsorbs apolipoproteins in plasma; wherein, The receptors include: LRP-1, SRB 1 and LRP-2; The sequence of the amyloid β short peptide is NH2-GSNKGAIIGLM-CONH2 from N to C terminus. The amyloid β short peptide is connected to polyethylene glycol-Z by a covalent bond to prepare SP-polyethylene glycol-Z, which is used to prepare a nano delivery system. In the SP-polyethylene glycol-Z, SP is an amyloid β short peptide, and Z is distearoylphosphatidylethanolamine DSPE; The amyloid β short peptide is modified on the surface of the nano-delivery system, wherein the amyloid β short peptide binds to apolipoprotein in plasma, thereby mediating the nano-delivery system to cross the blood-brain barrier; Wherein the nano delivery system is a liposome delivery system.

2. The use according to claim 1, characterized in that The nano-delivery system is used to encapsulate diagnostic molecules for tracing brain tumors.

3. The use according to claim 2, characterized in that: The diagnostic molecule is 5-carboxyfluorescein 5-FAM or near-infrared dyes Cy5, Cy5.5, Cy7, IR820, ICG, DiR, DiD, DiI.

4. The use according to claim 1, characterized in that The nano delivery system is used to encapsulate anti-tumor drugs and perform targeted intervention on brain tumors.

5. The use according to claim 4, characterized in that The drug is gefitinib, icotinib, anlotinib, crizotinib, erlotinib, osimertinib, alectinib, paclitaxel, docetaxel, cabazitaxel, doxorubicin, epirubicin, camptothecin, hydroxycamptothecin, 9-nitrocamptothecin, vincristine or p53 activating peptide.

6. The use according to any one of claims 1 to 5, characterized in that The brain tumor is a brain metastasis and / or a primary brain tumor.

7. A nano delivery system, characterized in that: The nano delivery system comprises SP-PEG-Z prepared by connecting an amyloid β short peptide to PEG-Z via a covalent bond; In the SP-polyethylene glycol-Z, SP is an amyloid β short peptide, and Z is distearoylphosphatidylethanolamine DSPE; The sequence of the amyloid β short peptide is NH2-GSNKGAIIGLM-CONH2 from N to C terminus. The amyloid β short peptide is modified on the surface of the nano-delivery system, wherein the amyloid β short peptide binds to apolipoprotein in plasma, thereby mediating the nano-delivery system to cross the blood-brain barrier; Wherein the nano delivery system is a liposome delivery system.

8. The nano delivery system according to claim 7, characterized in that The nano-delivery system is used to encapsulate diagnostic molecules and to track brain tumors or other brain disease lesions.

9. The nano delivery system according to claim 8, characterized in that The diagnostic molecule is 5-carboxyfluorescein 5-FAM or near-infrared dyes Cy5, Cy5.5, Cy7, IR820, ICG, DiR, DiD, DiI.

10. The nano delivery system according to claim 7, characterized in that The nano delivery system is used to encapsulate anti-tumor drugs and carry out targeted intervention of brain tumors or other brain disease lesions.

11. The nano delivery system according to claim 10, characterized in that The drug is gefitinib, icotinib, anlotinib, crizotinib, erlotinib, osimertinib, alectinib, paclitaxel, docetaxel, cabazitaxel, doxorubicin, epirubicin, camptothecin, hydroxycamptothecin, 9-nitrocamptothecin, vincristine or p53 activating peptide.

12. The nano delivery system according to any one of claims 7 to 11, characterized in that The brain tumor is a brain metastasis and / or a primary brain tumor.

13. A method for preparing the nano delivery system according to claim 7, characterized in that: The method comprises the following steps: Weighing natural phospholipids, cholesterol, methoxy-PEG-DSPE, SP-polyethylene glycol-DSPE, model drugs or probe molecules, dissolving them in a solvent, forming a film, hydrating, passing through the film, and removing free probe molecules or drugs by column chromatography to prepare the nano delivery system; and / or The nano delivery system is prepared by weighing natural phospholipids, cholesterol, methoxy-PEG-DSPE, and SP-polyethylene glycol-DSPE, dissolving them in a solvent, forming a film, hydrating, passing the film, actively encapsulating probe molecules or drugs, and removing free probe molecules or drugs by column chromatography.

14. A pharmaceutical composition, characterized in that The pharmaceutical composition comprises the nano delivery system according to any one of claims 7 to 12 and a pharmaceutically acceptable carrier.

15. A diagnostic preparation, characterized in that The diagnostic formulation comprises the nanodelivery system of any one of claims 7-12.